Bristows (London)

Matthew Hunt

Bristows (London)

Matthew is an associate with Bristows in the Competition & EU department in their London office. Matthew has been involved in a number of high-profile cases in the TMT sector. He was part of the team defending Google against an abuse of dominance claim brought by the online mapping company Streetmap, as well as the team representing Samsung in litigation issued by Unwired Planet relating to ‘FRAND’ aspects of standard essential patent licensing. He is currently involved in a number of on-going FRAND disputes, both for SEP holders and implementers. Matthew has significant experience dealing with the practical issues that arise during litigation, particularly in relation to: confidentiality; privilege; co-ordinating litigation across jurisdictions; and overlapping European Commission investigations, including disputes as to whether claims are follow-on or standalone. He has also spent time on secondment to the in-house litigation team of a leading technology company. Matthew regularly advises on issues arising out of distribution, licensing and settlement agreements, particularly in the pharmaceutical and TMT sectors. He also gives advice and training on competition law compliance, including on dawn raids. He is a regular contributor to the Bristows’ CLIP Board blog on the interface between competition and IP law, and has also written for publications including the Journal of European Competition Law & Practice, Competition Law Journal, and the Journal of Intellectual Property Law & Practice.

Linked authors

Bristows (London)
Bristows (Brussels)
Bristows (London)
Bristows (London)


267 Bulletin

Matthew Hunt, Stephen Smith The UK Court of Appeal considers the test for excessive pricing after an undertaking had charged unfairly high prices for phenytoin sodium capsules (Pfizer / Flynn)


Introduction In December 2016, the UK’s Competition and Markets Authority (CMA) found that Pfizer and Flynn had charged unfairly high prices for phenytoin sodium capsules, an important anti-epilepsy drug, in breach of competition law. The CMA imposed fines totalling £90 million. Pfizer and (...)


Total visits

Number of readings per contribution

Number of contributions

Author's ranking
In number of contributions
In number of visits
In average number of visits
Send a message